לברסט

Valsts: Izraēla

Valoda: ivrits

Klimata pārmaiņas: Ministry of Health

Aktīvā sastāvdaļa:

LETROZOLE 2.5 MG

Pieejams no:

RAFA LABORATORIES LTD

ATĶ kods:

L02BG04

Zāļu forma:

FILM COATED TABLETS

Ievadīšanas:

PER OS

Ražojis:

SIEGFRIED GENERICS ( MALTA) LTD

Ārstniecības grupa:

LETROZOLE

Ārstēšanas norādes:

Letrozole tablets are indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined locally advanced or metastatic breast cancer. Letrozole is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Autorizācija datums:

2012-04-01